Hwail Pharm KRX:061250KOSDAQ
화일약품 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked8since Sep 11
In Q2 2026, Hwail Pharm reported revenue of ₩24.5bn, down 12.5% year on year, and an operating loss of ₩912m. Hwail Pharm (화일약품) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 20 with 1 article. It was most often mentioned alongside ChoA Pharmaceutical and Samik Pharm.
Filing signals Control change Private placement Dilution risk Swung to loss Screener
Hwail Pharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩24.5bn | -12.5% | −₩912m margin −3.7% | ₩4.4bn |
| Q1 2026 | ₩23.4bn | -21.8% | −₩566m margin −2.4% | ₩579m |
| Q4 2025 derived | ₩18.6bn | -30.3% | −₩1.3bn margin −7.0% | −₩516m |
| Q3 2025 | ₩24.3bn | -17.9% | ₩165m margin 0.7% | ₩388m |
| Q2 2025 | ₩28.0bn | -11.6% | ₩51m margin 0.2% | ₩551m |
| Q1 2025 | ₩30.0bn | -6.0% | −₩1.2bn margin −4.0% | −₩657m |
| Q4 2024 derived | ₩26.6bn | -9.2% | −₩411m margin −1.5% | ₩5.8bn |
| Q3 2024 | ₩29.6bn | +3.1% | ₩140m margin 0.5% | ₩79m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Hwail Pharm top stories 2 weeks, by number of outlets
- 1
Latest Hwail Pharm news Korean headlines
-
Breaking화일약품, 100억원 규모 제3자배정 유상증자…파마앤바이오 신기술조합에 배정
1 more on this story · 1 outlets
- 화일약품, 100억원 유상증자…파마앤바이오 신기술조합에 제3자배정연합뉴스경제 · Sep 15 17:11